Crovalimab Gets First Nod In China For PNH, Fiercer Global Competition Awaits

 
• By Lisa Takagi

The anti-C5 inhibitor sets an example of swift global trial and approval in China while fiercer competition awaits in the US, Europe and Japan.

Crovalimab received global first approval in China and awaits approval decisions in the US, Europe and Japan.
Crovalimab receives global-first approval in China, awaits approval decisions in US, Europe and Japan • Source: Shutterstock

More from China

More from Focus On Asia